Fusion Pharmaceuticals Inc. (FUSN) News

Fusion Pharmaceuticals Inc. (FUSN): $3.30

0.20 (+6.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter FUSN News Items

FUSN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FUSN News Highlights

  • For FUSN, its 30 day story count is now at 5.
  • Over the past 16 days, the trend for FUSN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • BWXT are the most mentioned tickers in articles about FUSN.

Latest FUSN News From Around the Web

Below are the latest news stories about FUSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate FUSN as an investment opportunity.

A Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) insider increased their holdings by 370% last year

From what we can see, insiders were net buyers in Fusion Pharmaceuticals Inc.'s ( NASDAQ:FUSN ) during the past 12...

Yahoo | January 20, 2023

Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today reported continued progress across its pipeline of target alpha therapies (TATs) and provided recent corporate highlights.

Yahoo | January 6, 2023

Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

OTTAWA, Ontario--(BUSINESS WIRE)---- $BWXT--Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

Business Wire | January 5, 2023

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 38,000 shares of its common stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individual becoming an employe

Yahoo | January 4, 2023

2 “Strong Buy” Penny Stocks That Could Go Boom

With the New Year just a few days away, it’s time to start looking for the best portfolio choices going forward. This past year has been a mess for investors, and putting 2022’s bear market behind us will come as a relief – but finding solid choices for big gains will still require a high tolerance for risk. Fewer stock segments are more risky – or more potentially rewarding – than the penny stocks. Priced under $5 per share, these low-cost equities give investors a chance to double their money

Yahoo | December 22, 2022

Fusion Pharmaceuticals''s Return On Capital Employed Overview

Benzinga Pro data, Fusion Pharmaceuticals (NASDAQ: FUSN ) reported Q3 sales of $166 thousand. Earnings fell to a loss of $24.01 million, resulting in a 25.9% decrease from last quarter. Fusion Pharmaceuticals collected $570 thousand in revenue during Q2, but reported earnings showed a $19.07 million loss. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com

Benzinga | December 6, 2022

JonesTrading Sticks to Its Buy Rating for Fusion Pharmaceuticals (FUSN)

JonesTrading analyst Justin Walsh maintained a Buy rating on Fusion Pharmaceuticals (FUSN - Research Report) on November 8 and set a price target of $10.00. The company's shares opened today at $2.18.According to TipRanks, Walsh is an analyst with an average return of -31.1% and a 19.05% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, POINT Biopharma Global, and Plus Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fusion Pharmaceuticals with a $10.00 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $8.73 and a one-year low of $1.98.

Austin Angelo on TipRanks | November 10, 2022

Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates

FPI-1434 Phase 1 data on track to be reported in first half of 2023 Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3 Strong balance sheet with $205.5 million in cash, cash equivalents and investments with runway into Q3 2024 HAMILTON, ON and…

PR Newswire | November 8, 2022

Fusion Pharmaceuticals GAAP EPS of -$0.55 misses by $0.04, revenue of $0.17M beats by $0.07M

Fusion Pharmaceuticals press release (FUSN): Q3 GAAP EPS of -$0.55 misses by $0.04.Revenue of $0.17M (-46.9% Y/Y) beats by $0.07M.As of September 30, 2022, Fusion held cash,…

Seeking Alpha | November 8, 2022

Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5093 seconds.